IL17A and psoriasis vulgaris: Policy makers might need to create strategies to control IL-17 inhibitors price and improve the accessibility to all IL-17 inhibitors as a sequential treatment for patients with moderate-to-severe plaque psoriasis who previously failed one of IL-17 inhibitors in a real-world setting.